Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times ...
Predictors of attrition in the treatment of metastatic colorectal cancer (MCRC). Neuroendocrine tumor (NET) patient (pt) experience with disease management: Results from the first global NET pt survey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback